US › Healthcare

Lineage Cell Therapeutics Inc (LCTX)

US · Healthcare · Biotechnology

$1.02+4.08%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

$1.1M

Revenue YoY

-61.3%

Net profit

$1.5M

EPS

$-0.03

EPS estimate

$-0.03

Net margin

138.6%

EPS came in at -0.03 against a street estimate of -0.03 — a beat of 0.0%.

Key statistics

Market cap

$248.6M

Forward P/E

30.7

P/B

4.28

Book value

$0.24

EPS (TTM)

$-0.19

52-week high

$1.99

52-week low

$0.88

50-day MA

$1.01

200-day MA

$1.32

Beta

1.69

Analyst view

Analysts rate Lineage Cell Therapeutics Inc a buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $5.50.

Shareholding

Insiders

4.86%

Institutions

48.45%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lineage Cell Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.